

with major anatomical difficulties, marked edema, or hematoma, a percutaneous technique may be facilitated by ultrasonography.⁵

Nicolas Libert, M.D.

Thomas Leclerc, M.D.

Stéphane De Rudnicki, M.D.

Hôpital d'Instruction des Armées du Val de Grâce
75005 Paris, France
nicolaslibert@free.fr

1. Combes X, Pean D, Lenfant F, Francon D, Marciniak B, Legras A. Difficult airway-management devices: establishment and maintenance: question 4. *Ann Fr Anesth Reanim* 2008;27:33-40. (In French.)
2. Benkhadra M, Lenfant F, Nemetz W, Anderhuber F, Feigl G, Fasel J. A comparison of two emergency cricothyroidotomy kits in human cadavers. *Anesth Analg* 2008;106:182-5.
3. Schaumann N, Lorenz V, Schellongowski P, et al. Evaluation of Seldinger technique emergency cricothyroidotomy versus standard surgical cricothyroidotomy in 200 cadavers. *Anesthesiology* 2005;102:7-11.
4. Assmann NM, Wong DT, Morales E. A comparison of a new indicator-guided with a conventional wire-guided percutaneous cricothyroidotomy device in mannequins. *Anesth Analg* 2007;105:148-54.
5. Sustić A. Role of ultrasound in the airway management of critically ill patients. *Crit Care Med* 2007;35:Suppl:S173-S177.

TO THE EDITOR: In their video on cricothyroidotomy, Hsiao and Pacheco-Fowler show a technique that is ideal for experienced physicians. However, in some circumstances, cricothyroidotomy may also be performed by paramedics and nurses in the prehospital setting or by relatively inexperienced physicians in the hospital. Many of these

providers do not have tracheal hooks and Trouseau dilators available to them.

In addition, a number of potentially catastrophic complications, such as time delays and placement of the tracheostomy or endotracheal tube in a false passage, are not mentioned in the video.^{1,2} Some studies have reported complication rates as high as 54% in the medical air-transport setting.³

We advocate the use of a gum elastic bougie, which is also called an endotracheal-tube introducer, to facilitate surgical cricothyroidotomy. This approach has been described by MacIntyre et al. as the "three-step" technique.⁴ Our experience in both the cadaver laboratory and prehospital setting indicates that this approach obviates the need for any equipment other than a tracheostomy or endotracheal tube, bougie, and scalpel.

Darren A. Braude, M.D.

Steve McLaughlin, M.D.

University of New Mexico
Albuquerque, NM 87131
dbraude@salud.unm.edu

1. Schroeder AA. Cricothyroidotomy: when, why, and why not? *Am J Otolaryngol* 2000;21:195-201.
2. Issacs JH Jr, Pedersen AD. Emergency cricothyroidotomy. *Am Surg* 1997;63:346-9.
3. Bair AE, Panacek EA, Wisner DH, Bales R, Sakles JC. Cricothyrotomy: a 5-year experience at one institution. *J Emerg Med* 2003;24:151-6.
4. MacIntyre A, Markarian MK, Carrison D, Coates J, Kuhls D, Fildes JJ. Three-step emergency cricothyroidotomy. *Mil Med* 2007;172:1228-30.


Fatal Oseltamivir-Resistant Influenza Virus Infection

TO THE EDITOR: The incidence of influenza A (H1N1) viruses that carry the neuraminidase H274Y mutation has increased by 30% this year in the Netherlands.¹ Influenza A (H1N1) viruses that carry this mutation are resistant to oseltamivir but remain sensitive to zanamivir.² However, these mutant viruses are considered to have attenuated pathogenicity.^{3,4}

A 67-year-old man who had received a diagnosis of chronic lymphocytic leukemia 3 years earlier was admitted to the hospital because of dyspnea, dry cough, and fever. One week before admission, he had received a course of cyclophosphamide, vincristine, and prednisolone chemotherapy. At admission, his white-cell count was 137,000 per cubic millimeter, with 99% lymphocytes and no neutrophils. Because of acute respiratory failure, empirical antibacterial therapy was

Figure 1 (facing page). Leukocyte Counts, Viral Loads, and Treatment during the Hospital Course in a Patient Infected with Influenza A (H1N1) Virus with the H274Y Mutation.

Panel A shows the patient's granulocyte and monocyte counts. The gradual increase in the granulocyte count was consistent with bone marrow recovery. Panel B shows the viral load in the respiratory specimens. The dashed red line indicates the lower limit of detection. Various therapeutic and empirical antiviral therapies, shown in Panel C, and antibacterial and antifungal therapies, shown in Panel D, were given to the patient at different intervals (shaded bars). The red portions of the bars in Panel C indicate detection of resistance mutations for either oseltamivir (neuraminidase H274Y) or amantadine (M2-channel L26F), and the blue boxes indicate detection of the wild-type genotype. The L26F resistance mutation in the M2 protein was detected only on day 20, whereas the H274Y mutation was present before and after oseltamivir was administered.



initiated, and mechanical ventilation was required by the second hospital day (Fig. 1). Computed tomography (CT) revealed patchy infiltrates in both lungs, and influenza A (H1N1) virus was detected in respiratory secretions. During the entire hospital course, no other respiratory pathogens were detected in bronchoalveolar-lavage specimens. The only other pathogens identified in blood cultures were *Candida albicans* and *Enterococcus faecium*, for which fluconazole and vancomycin were given.

Oseltamivir was administered for the influenza virus infection, beginning on the sixth hospital day, but it was discontinued on day 13 because sequence analysis revealed the H274Y mutation, and no decrease in the viral load was observed. In retrospect, the H274Y mutation was present in the specimen obtained before oseltamivir therapy was initiated. The patient's hospital record and his family indicated that he had had no contact with patients who had received oseltamivir. On day 15, amantadine was added to the patient's treatment regimen. Four days later, the neutrophil count increased, indicating bone marrow recovery. Mechanical ventilation was discontinued on day 20, and zanamivir by inhalation was initiated. However, respiratory failure occurred on day 22, mechanical ventilation was reinstated, and therapy with zanamivir was discontinued. On day 26, the influenza virus was no longer detectable. Because sequence analyses showed an amantadine-resistance mutation in the viral M2 protein (L26F) and zanamivir therapy had

been limited to three doses, clearance of the virus was probably due to recovery of the immune system. A second CT scan, obtained on day 28, revealed progression of the pulmonary infiltrates. Because of the poor prognosis, mechanical ventilation was discontinued on day 34. The patient died 3 days later.

It has been suggested that the H274Y mutation, which confers resistance to oseltamivir, leaves the influenza A (H1N1) virus severely compromised.^{3,4} However, the case we describe suggests that this oseltamivir-resistant virus can be pathogenic, at least in an immunocompromised patient.

Erhard van der Vries, M.Sc.
Bart van den Berg, M.D., Ph.D.
Martin Schutten, Ph.D.
Erasmus University Medical Center
3015 CE Rotterdam, the Netherlands

Dr. Schutten reports receiving lecture fees from Roche Diagnostics, the Netherlands. No other potential conflict of interest relevant to this letter was reported.

1. World Health Organization. Epidemic and Pandemic Alert and Response (EPR): influenza A(H1N1) virus resistance to oseltamivir — last quarter 2007 to 5 May 2008. (Accessed August 15, 2008, at <http://www.who.int/csr/disease/influenza/H1N1ResistanceWeb20080505.pdf>.)
2. Ferraris O, Lina B. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. *J Clin Virol* 2008;41:13-9.
3. Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. *Antivir Res* 2002;55:307-17.
4. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. *J Infect Dis* 2004;190:1627-30.

Correspondence Copyright © 2008 Massachusetts Medical Society.

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following: •Letters in reference to a *Journal* article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article. Letters not related to a *Journal* article must not exceed 400 words. All letters must be submitted over the Internet at <http://authors.nejm.org>. •A letter can have no more than five references and one figure or table. •A letter can be signed by no more than three authors. •Financial associations or other possible conflicts of interest must be disclosed. (Such disclosures will be published with the letters. For authors of *Journal* articles who are responding to letters, this information appears in the published articles.) •Include your full mailing address, telephone number, fax number, and e-mail address with your letter.

Our Web site: <http://authors.nejm.org>

We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. Letters that do not adhere to these instructions will not be considered. Rejected letters and figures will not be returned. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the *Journal*'s various print and electronic publications and in collections, revisions, and any other form or medium.